CHART – Cancer and Haematology Academic Research Team

What we do

The Cancer & Haematology Academic Research Team (CHART) is a Clinical Trial Operations team acting as the Sponsor Coordination Centre for national and international investigator-initiated trials (IITs), sponsored by both Imperial College London and Imperial College Healthcare NHS Trust (ICHNT). As well as coordinating ICL/ICHNT-sponsored research, CHART also acts as a Contract Research Organisation (CRO) for externally academic or commercially sponsored research.

CHART supports a full range of clinical operations activities, including:

• Study design and study document development
• Costing
• Contract management
• Site set-up and management
• Trial management and oversight
• Monitoring
• Data management
• Pharmacovigilance  

Our team members work closely with the ICHNT Research Delivery teams, supporting continuous collaboration with our lead site during study set-up, activation and recruitment to our trials. We also keep updated with evolving trial set-up and delivery pathways in the NHS, facilitating faster turnaround in trial activities.

We are fortunate to work with world-renowned Chief Investigators from the initial stages of protocol development, through to results analysis and publication.  CHART also collaborates closely with the Imperial Clinical Trials Unit (ICTU) and the Research Governance & Integrity Team (RGIT) to ensure our studies are operated to the highest ethical and regulatory standards.

Summary of current research

CHART manages a diverse portfolio of different cancer and haematology clinical trials, including Clinical Trials of Investigational Medicinal Products (CTIMPs), radiopharmaceutical trials, surgical trials and observational research conducted across the UK, EU, US and Asia. Please see list of current studies below.

Clinical Trials

Trials Open to Recruitment

• Precision HCC | Molecular markers to enable precision medicine in Hepatocellular Cancer.
• LANTana | LANTana: Lutathera and ASTX727 in Neuroendocrine Tumours.
• FLiCIR | Fibrolamellar Hepatocellular Cancer Registry.
• GUMBIT | A pilot study to investigate the gut microbiome in patients with immune thrombocytopenia (ITP)
• MRI scan to investigate microbleeds in Thrombocytopenic patients | Can we detect subclinical brain micro haemorrhages in patients with thrombocytopenia using susceptibility sensitive MRI in order to better direct treatment
• VMS/Sleep | Examining the relationship between vasomotor symptoms (VMS) and sleep disturbances in prostate cancer patients receiving androgen deprivation therapy (ADT) - a prospective study using a combination of questionnaires and actigraphy

Trials closed to recruitment:

• STARKAP | Study fo TSR-042 in the treatment of HIV-associated combination antiretroviral therapy (cART) refractory kaposi Sarcoma.
• PELICAN | A phase II study of etoposide-carboplatin (EP) chemotherapy in combination with pembrolizumab and lenvatinib maintenance in advanced high-grade neuroendocrine tumours (HG-NETs).r
• ProGREsS | Personalised Genetic Risk Estimates for Cancer Screening & Prevention. 
• HELP-ER | Prospective Study of HE4 serum Level in Patients with First Relapsed Ovarian Cancer.
• VIGILANT | naVIGation Invitations Liver surveillANce upTake
• ATB/Antibiotic ICPI | Qualification of antibiotic-induced gut perturbation as a therapeutically actionable driver of anti-cancer immunity. 

Closed trials

• PRIME-HCC | Preliminary assessment of safety and bioactivity of the Ipilimumab and Nivolumab combination prior to liver resection (LR) in hepatocellular carcinoma (HCC). 
• JAKaL | A phase Ib study of INCB039110, a JAK1 inhibitor, in advanced hepatocellular carcinoma.
• PETAL | A Phase Ib Study of Pembrolizumab following Trans-Arterial Chemoembolization
  in Primary Liver Carcinoma MK3475-540.
• ArTisaN | A Phase II Assessment of the Safety and Efficacy of TheraSphere® Selective Internal Radiation Therapy (SIRT) in the treatment of Metastatic (Liver) Neuroendocrine Tumours (NETs).
• Shortened hydration | A prospective study of tolerance comparing the current hydration regimen for the ABC02 chemotherapy regimen versus a shorter hydration protocol.
• On-Covid | OnCovid: natural history and outcomes of cancer patients during the COVID19 epidemic.
• AXMUS C | A phase II double blind, randomised controlled trial of vegf inhibitor axitinib monotherapy with early dynamic contrast enhanced ultrasound monitoring in chemorefractory third line metastatic colorectal cancer.
• PRIMAL | F-18 Fluoro-L-Thymidine PET for assessment of treatment Response to Immunotherapy Cancer: PRIMal study.
• MATIS | Multi-arm trial of Inflammatory Signal Inhibitors for COVID-19 (MATIS).
• RHEPaiR | Safety & efficacy of individualized dosing using the Holium platform in patients with unresectable Hepatocellular Cancer.
• NELMAS (NET with liver met) | Management of neuroendocrine liver metastases in adjuvant setting.